A Phase 2 Trial of Abiraterone Acetate Without Glucocorticoids for Men With Metastatic Castration-Resistant Prostate Cancer

Cancer - United States
doi 10.1002/cncr.31836
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Olaparib Combined With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial

The Lancet Oncology
Oncology
2018English

Exploratory Analysis of the Visceral Disease Subgroup in a Phase III Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer and Prostatic Diseases
Cancer ResearchOncologyUrology
2013English

A Prognostic Model for Stratifying Clinical Outcomes in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate

Canadian Urological Association Journal
Urology
2017English

Prostate-Specific Antigen Decline After 4 Weeks of Treatment With Abiraterone Acetate and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer

European Urology
Urology
2016English

Mp50-20 Impact of Abiraterone Acetate in Prostate Specific Antigen Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients With Non-Metastatic Castration-Resistant Prostate Cancer

Journal of Urology
Urology
2016English

Remarkable Response to Abiraterone Acetate in Castration-Resistant Prostate Cancer Patient With Aggressive Liver Metastasis

IJU Case Reports
2018English

Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Efficacy and Safety in Unselected Patients

Cancer Treatment and Research Communications
Cancer ResearchOncology
2018English

Phase III Data for Abiraterone in an Evolving Landscape for Castration-Resistant Prostate Cancer

Maturitas
BiochemistryGynecologyGeneticsObstetricsMolecular Biology
2011English

Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial

The Lancet Oncology
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy